YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Vincristine Induced Cranial Polyneuropathy

dc.authorscopusid 55640373400
dc.authorscopusid 8421729700
dc.authorscopusid 55875007400
dc.authorscopusid 7005791514
dc.contributor.author Ali, B.
dc.contributor.author Yilmaz, C.
dc.contributor.author Yilmaz, N.
dc.contributor.author Oner, A.F.
dc.date.accessioned 2025-05-10T17:06:29Z
dc.date.available 2025-05-10T17:06:29Z
dc.date.issued 2006
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Ali B., Yuzuncu Yil University Faculty of Medicine, Division of Hematology, Turkey, Dr. Yuzuncu Yyl University Tip Fak. Arastirma Hastanesi Cocuk Servisi, 65200 Van, Mara Caddesi, Turkey; Yilmaz C., Yuzuncu Yil University Faculty of Medicine, Division of Neurology, Van, Turkey; Yilmaz N., Yuzuncu Yil University Faculty of Medicine, Division of Neurosurgery, Van, Turkey; Oner A.F., Yuzuncu Yyl University Faculty of Medicine, Van, Turkey en_US
dc.description.abstract We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment. A 5-year-old girl was diagnosed preB cell Acute Lymphoblastic Leukemia (ALL). She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII. Five days after the fourth dose of vincristine, she presented with bilateral ptosis. Neurological examination revealed bilateral ptosis, and complete external opthalmoplegia with normal pupillary and corneal reflexes. She received 3.8 mg cumulative dose of vincristin before development of ptosis. A neuroprotective and neuroregenerative treatment attempt with pyridoxine and pyridostigmine was initiated. The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks. The both agents were given for 3 weeks and were well tolerated without any side effects. During the follow up period we did not observe residue or recurrence of the ptosis. en_US
dc.identifier.doi 10.1007/BF02759902
dc.identifier.endpage 533 en_US
dc.identifier.issn 0019-5456
dc.identifier.issue 6 en_US
dc.identifier.pmid 16816519
dc.identifier.scopus 2-s2.0-33746749543
dc.identifier.scopusquality Q1
dc.identifier.startpage 531 en_US
dc.identifier.uri https://doi.org/10.1007/BF02759902
dc.identifier.uri https://hdl.handle.net/20.500.14720/6426
dc.identifier.volume 73 en_US
dc.identifier.wosquality Q1
dc.language.iso en en_US
dc.relation.ispartof Indian Journal of Pediatrics en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Ptosis en_US
dc.subject Treatment en_US
dc.subject Vincristine en_US
dc.title Vincristine Induced Cranial Polyneuropathy en_US
dc.type Article en_US

Files